NCT06723171View on ClinicalTrials.gov

Evaluation of Safety and Efficacy of IRX4204 in Mild to Moderate Plaque Psoriasis

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

April 30, 2026

Conditions

PsoriasisPlaque Type PsorisisPlaque Psoriasis

Interventions

DRUG

IRX4204

Active Treatment

OTHER

Placebo

Placebo

Trial Locations (1)

77598

Not posted, Webster

Sponsors

Lead Sponsor

Io Therapeutics

All Listed Sponsors

lead

Io Therapeutics

INDUSTRY